Condition (MeSH)
Granulomatosis with Polyangiitis
ClinicalTrials.gov lists 104 trials for Granulomatosis with Polyangiitis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 12.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
104 of the 104 trials are tagged with Granulomatosis with Polyangiitis itself; the rest are tagged with a narrower condition beneath it.
When did Granulomatosis with Polyangiitis trials start? (31)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 6 |
| 2024 | 5 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 4 |
| 2019 | 5 |
| 2018 | 4 |
| 2017 | 1 |
Showing 10 of 31 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 12 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 52 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Granulomatosis with Polyangiitis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 1/2 | 4 |
| Phase 2 | 21 |
| Phase 2/3 | 5 |
| Phase 3 | 15 |
| Phase 4 | 13 |
| Not applicable | 6 |
| Observational | 33 |
How many Granulomatosis with Polyangiitis trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 14 |
| Active, not recruiting | 5 |
| Completed | 54 |
| Terminated | 11 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Granulomatosis with Polyangiitis trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 12 |
| Hoffmann-La Roche | 2 |
| InflaRx GmbH | 2 |
| Novartis Pharmaceuticals | 2 |
| Alpine Immune Sciences, Inc. | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Granulomatosis with Polyangiitis? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 20 |
| Cytoxan | 8 |
| Prednisone | 6 |
| METHYLPREDNISOLONE | 5 |
| Belimumab | 3 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Azathioprine Pill | 7 |
| Glucocorticoids | 4 |
| Abatacept SC | 4 |
| Mofetil Mycophenolate | 4 |
| Plasma Exchange | 3 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Granulomatosis with Polyangiitis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Infection | 250 | 1 |
| Other | 168 | 1 |
| Cardiovascular | 124 | 1 |
| Renal | 77 | 1 |
| Gastrointestinal | 73 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Granulomatosis with Polyangiitis? (108)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial. | Annals of internal medicine | 2025 | Yes |
| EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. | Annals of the rheumatic diseases | 2024 | Yes |
| Dysregulation of neutrophil oxidant production and interleukin-1-related cytokines in granulomatosis with polyangiitis. | Rheumatology (Oxford, England) | 2024 | Yes |
| Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. | Nature reviews. Rheumatology | 2023 | Yes |
| Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study. | The Lancet. Rheumatology | 2023 | Yes |
Showing 5 of 108 publications.
Prevalence (75)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Granulomatosis with polyangiitis | Annual incidence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Granulomatosis with polyangiitis | Annual incidence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Granulomatosis with polyangiitis | Annual incidence | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Granulomatosis with polyangiitis | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Granulomatosis with polyangiitis | Point prevalence | 1-9 / 100 000 | United States | US | Exact |
Showing 5 of 75 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Granulomatosis with polyangiitis | 900 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Granulomatosis with polyangiitis | 900 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.